Ces Urol 2016, 20(3):214-220 | DOI: 10.48095/cccu2016027

Cabazitaxel for the treatment of metastatic castration-resistant prostate cancer

Igor Richter^1,2, Josef Dvořák², Věra Hejzlarová¹, Eva Čermáková³, Jiří Bartoš¹

¹ Onkologické oddělení, Krajská nemocnice Liberec, a.s.

² Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

³ Ústav informatiky a biofyziky, Univerzita Karlova v Praze, Lékařská fakulta v Hradci Králové

Richter I, Dvořák J, Hejzlarová V, Čermáková E, Bartoš J. Cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Major statement: Cabazitaxel is a new therapeutic option in patients with metastatic castration-resistant prostate cancer (mCRPC). We presented a retrospective evaluation of toxicity and efficacy in 14 patients with mCRPC treated by cabazitaxel Aim: A retrospective evaluation of efficacy and torerance of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Methods: A total of 14 patients with mCRPC after previous treatment of docetaxel were evaluated. Cabazitaxel was administered in dose 25 mg/m² every 3 weeks concomitantly with daily Prednisolone 10 mg. We evaluated overall survival (OS) and progression free survival (PFS).

Results: The median of follow-up was 16.5 months. The median of OS was 9.6 months (95 % CI 7.5-22 months). The 2-year OS was described in 23.45 % (95 % CI 0-59 %) of patients. The median of PFS was 5.5 months (95 % CI 2.7-10.8 months). The toxicity was predominantly grade I or II. Toxicity Grade III - IV: anemia in 2 patients, leucopenia in 1 patient, hematuria in 1 patient, heart failure in 1 patient.

Conclusion: Cabazitaxel demonstrated favorable profile of toxicity and efficacy in treatment of metastatic castration-resistant prostate cancer in clinical practice.

Keywords: Karcinom prostaty, metastázy, chemoterapie, docetaxel, kabazitaxel.

Received: March 6, 2016; Accepted: June 15, 2016; Prepublished online: August 4, 2016; Published: September 30, 2016